

# Enzymatic Resolution of ( $\pm$ )-2-*Exo*-7-*syn*-7-(1-propynyl)norbornan-2-ol, a Key Synthetic Intermediate for Jasmonoids

Hiromasa Kiyota, Daisuke Nakashima,  
Shigefumi Kuwahara, and Takayuki Oritani

Department of Bioscience and Biotechnology for Future  
Bioindustry, Graduate School of Agricultural Science,  
Tohoku University, 1-1 Tsutsumidori-Amamiya, Aoba-ku,  
Sendai, 981-8555 Japan

Reprint requests to Dr. Hiromasa Kiyota,  
Tel. and Fax: +81 22 717 8785.  
E-mail: kiyota@biochem.tohoku.ac.jp

*Z. Naturforsch.* **2008**, *63b*, 1441 – 1442;  
received June 25, 2008

Lipase-catalyzed resolution of 2-*exo*-7-*syn*-7-(1'-propynyl)norbornan-2-ol, a key synthetic intermediate for jasmonoids, was achieved using vinyl chloroacetate as an acyl donor.


**Key words:** Enzymatic Resolution, Lipases,  
Transesterification, Chloroacetate,  
Bicyclo[2.2.1]heptan-2-ol

## Introduction


Jasmonoids are distributed as various biologically active compounds such as plant hormones [1] and perfumes [2], and sometimes show even therapeutic activity [3]. We have achieved the total synthesis of methyl tuberonate (**1**), a strong potato tuber-forming substance, in a racemic form [4] from norbornene (Scheme 1). In order to prepare the optically active product, we focused on the enzymatic resolution of the synthetic intermediate alcohols such as **2**. Enzymatic reaction has been one of the methods of choice to get optically active organic compounds under mild conditions [5]. Here we describe the results of the resolution of the sterically hindered alcohol ( $\pm$ )-**2**.

## Results and Discussion

At first, transacetylation of ( $\pm$ )-**2** and hydrolysis of its acetate ( $\pm$ )-**3** were tried, however, neither proceeded using various commercial lipases and esterases. Then the more reactive chloroacetyl group



Scheme 1. Synthesis of ( $\pm$ )-methyl tuberonate (**1**).



Scheme 2. Enzymatic resolution of ( $\pm$ )-**2**. (a)  $\text{Ac}_2\text{O}$ , Py (99%); (b) chloroacetyl chloride, Py,  $\text{Et}_2\text{O}$  (92%); (c) Chirazyme<sup>®</sup> L-9, c.-f., C2, lyo., *i*-Pr<sub>2</sub>O, 20 °C; (d) i. 3,5-dinitrobenzoyl chloride, pyridine, DMAP,  $\text{Et}_2\text{O}$  (quant.); ii. recrystallization from *i*-Pr<sub>2</sub>O (58%); (e) i. PDC,  $\text{CHCl}_3$ ; ii.  $\text{H}_2$ , Pd-C, MeOH.

was introduced. Transesterification of ( $\pm$ )-**2** with vinyl chloroacetate catalyzed by Chirazyme<sup>®</sup> L-9 (*Mucor miehei*, Roche) afforded (-)-**2** (88% ee) and chloroacetate (-)-**4** at 57% conversion (Scheme 2). The enantiomeric purity was determined by HPLC analysis of the corresponding MTPA ester, and the E value was calculated as 14. Enzymatic hydrolysis of ( $\pm$ )-**4** resulted in poor selectivity. The product (-)-**2** was further purified by recrystallization of its 3,5-dinitrobenzoate **5** up to > 99% ee. The product of another run (-)-**2** (73% ee) was converted into its saturated keto derivative **6** to determine the absolute configuration. The sign of optical rotation of **6** ( $[\alpha]_{\text{D}}^{18} = +24^\circ$  ( $c = 0.25$ , MeOH)) compared with those of (+)-norcamphor ( $[\alpha]_{\text{D}} = +31^\circ$ ) and (+)-camphor ( $[\alpha]_{\text{D}}^{20} = +54.9^\circ$  ( $c = 5$ , EtOH)) revealed the stereochemistry as drawn in Scheme 2 [6]. The similar Cotton curves of **6** and (+)-camphor in the CD spectra also support this conclusion.

The alcohols **2** resolved in this experiment will be useful chiral building blocks for valuable compounds. The results also have exemplified a lipase-catalyzed transesterification of a rather hindered hydroxy group.

## Experimental Section

### General

Optical rotation: Horiba SEPA-300. NMR: Varian Gemini 2000 (300 MHz) and Varian Inova 500 (500 MHz). IR: Jasco Report-100. MS: Jeol JMS-700. HPLC: Hitachi L-6000 pump & Hitachi L-4200 UV/Vis detector. Column chromatography: Merck silica gel 60 (70–230 mesh).

#### (1*S*\*,2*S*\*,4*S*\*,7*R*\*)-7-(1'-Propynyl)bicyclo[2.2.1]hept-2-yl acetate ((±)-**3**)

To a solution of (±)-**2** (1.68 g, 11.2 mmol) in pyridine (3.4 g, 43 mmol) was added Ac<sub>2</sub>O (4.08 g, 40.0 mmol) at 20 °C, and the mixture was stirred for 12 h at 20 °C, then diluted with Et<sub>2</sub>O, dil. HCl (5 times), sat. aq. NaHCO<sub>3</sub> soln. and brine, dried with MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was chromatographed on SiO<sub>2</sub> (hexane/EtOAc = 30:1) to give (±)-**3** (2.12 g, 99 %) as a colorless oil. – IR:  $\nu$  = 3060 (s), 1730 (s, C=O), 1360 (m), 1245 (s, C–O), 1220 (m), 1080 (s), 1045 (m), 1020 (m) cm<sup>–1</sup>. – <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.13 (d, *J* = 4.9 Hz, 1 H), 1.15 (d, *J* = 4.9 Hz, 1 H), 1.42–1.62 (m, 2 H), 1.81 (d, *J* = 2.4 Hz, 3 H, CH<sub>3</sub>C≡), 1.85–1.9 (m, 1 H), 1.95–2.0 (m, 1 H), 2.03 (s, 3 H, CH<sub>3</sub>C=O), 2.30 (m, 2 H), 2.41 (d, *J* = 4.1 Hz, 1 H), 4.58 (dd, *J* = 7.4, 3.6 Hz, 1 H, 2-H). – MS (EI): *m/z* = 117 [M–AcOH–CH<sub>3</sub>]<sup>+</sup>, 132 [M–AcOH]<sup>+</sup>, 150 [M+H–Ac]<sup>+</sup>, 177 [M–CH<sub>3</sub>]<sup>+</sup>, 192 M<sup>+</sup>. – HRMS (EI): *m/z* = 192.1150 (calcd. 192.1150 for C<sub>12</sub>H<sub>16</sub>O<sub>2</sub>, M<sup>+</sup>).

#### (1*S*\*,2*S*\*,4*S*\*,7*R*\*)-7-(1'-Propynyl)bicyclo[2.2.1]hept-2-yl chloroacetate ((±)-**4**)

To a solution of (±)-**2** (150 mg, 0.999 mmol) and pyridine (0.50 g, 6.3 mmol) in dry Et<sub>2</sub>O was added chloroacetyl chloride (339 mg, 2.98 mmol) at –20 °C. The mixture was stirred for 12 h at 20 °C, then diluted with Et<sub>2</sub>O, washed with dil. HCl (5 times), sat. aq. NaHCO<sub>3</sub> soln. and brine, dried with MgSO<sub>4</sub> and concentrated *in vacuo*. The residue

was chromatographed on SiO<sub>2</sub> (hexane/EtOAc = 30:1) to give (±)-**4** (209 mg, 0.922 mmol, 92 %) as a colorless oil. – IR:  $\nu$  = 3100 (s), 1750 (s, C=O), 1720 (s, C=O), 1340 (m), 1310 (s), 1180 (s), 1070 (m), 1040 (m), 1045 (m), 1000 (m), 980 (m) cm<sup>–1</sup>. – <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.1–1.2 (m, 2 H), 1.50–1.64 (m, 2 H), 1.79 (d, *J* = 1.5 Hz, 3 H, CH<sub>3</sub>), 1.89 (dd, *J* = 13.5, 8.0 Hz, 1 H), 2.04 (dq, *J* = 13.5, 3.0 Hz, 1 H), 2.30–2.36 (m, 2 H), 2.46 (d, *J* = 4.5 Hz, 1 H), 4.03 (s, 2 H, CH<sub>2</sub>Cl), 4.69 (dd, *J* = 7.5, 3.0 Hz, 1 H, 2-H). – MS (FAB): *m/z* = 133 [M+H–ClCH<sub>2</sub>COOH]<sup>+</sup>, 149 [M–ClCH<sub>2</sub>CO]<sup>+</sup>, 177 [M–CH<sub>3</sub>]<sup>+</sup>, 225, 227 M<sup>+</sup>. – HRMS (FAB, NOBA+PEG+NaCl): *m/z* = 227.0835 (calcd. 227.0838 for C<sub>12</sub>H<sub>16</sub>O<sub>2</sub><sup>37</sup>Cl, [M]<sup>+</sup>).

#### (–)-(1*S*,2*S*,4*S*,7*R*)-**3** (lipase-catalyzed transesterification)

A suspension of (±)-**2** (150 g, 1.00 mmol), vinyl chloroacetate (0.30 mL, 0.36 g, 3.0 mmol, 3 eq.) and Chirazyme<sup>®</sup> L-9, c.-f., C2, lyo. (50 mg, 0.65 units) in *i*-Pr<sub>2</sub>O (5 mL) was stirred at 20 °C for 6 h, and the mixture was filtered through a Celite pad. The filtrate was concentrated *in vacuo*. The residue was chromatographed on silica gel (hexane/EtOAc = 10:1) to give (–)-**3** [129 mg, 0.57 mmol, 57 %, [ $\alpha$ ]<sub>D</sub><sup>23</sup> = –16.2° (*c* = 1.05, *i*-Pr<sub>2</sub>O)] and (–)-**2** [65 mg, 0.43 mmol, 43 %, [ $\alpha$ ]<sub>D</sub><sup>23</sup> = –8.1° (*c* = 0.93, *i*-Pr<sub>2</sub>O)] as colorless oils.

#### HPLC Analysis of the MTPA esters

Column: Daicel Chiralcel<sup>®</sup> OD (4.6 × 250 mm); eluent: hexane/*i*-PrOH = 100:1, 1.0 mL min<sup>–1</sup> at 20 °C; detection: 254 nm; *t*<sub>R</sub> = 70 (80.1 %) and 9.5 (4.9 %) min: 88 % ee.

#### HPLC Analysis of the 3,5-DNB ester

Column: Daicel Chiralcel<sup>®</sup> OD (4.6 × 250 mm); eluent: hexane/*i*-PrOH = 9:1, 1.0 mL min<sup>–1</sup> at 20 °C; detection: 254 nm; *t*<sub>R</sub> = 28 (< 0.5 %) and 38 (> 99.5 %) min: > 99 % ee.

#### Acknowledgements

We thank Roche Diagnostics K. K. for the gifts of various lipases. This work was partially supported by a Grant-in-aid for Scientific Research from the Japan Society for the Promotion of Science (19580120).

- [1] M. H. Beale, J. L. Ward, *Nat. Prod. Rep.* **1998**, *15*, 533–548.
- [2] P. Kraft, J. A. Bajgrowicz, C. Denis, G. Fráter, *Angew. Chem.* **2000**, *112*, 3106–3138; *Angew. Chem. Int. Ed.* **2000**, *39*, 2980–3010.
- [3] Y. Ishii, H. Kiyota, S. Sakai, Y. Honma, *Leukemia* **2004**, *18*, 1413–1419.
- [4] H. Kiyota, D. Nakashima, T. Oritani, *Biosci. Biotechnol. Biochem.* **1999**, *63*, 2110–2117.
- [5] F. Theil, *Chem. Rev.* **1995**, *95*, 2203–2227.
- [6] *Dictionary of Organic Compounds*, Vol. 1 (5<sup>th</sup> Ed.) (Ed.: J. Buckingham), Chapman and Hall, New York, London, Toronto, **1982**, pp. 970–971.